Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM

Stopped Study withdrawn, trial therapy deemed no longer novel and there was a lack of site interest.

Conditions

• Relapsed or Refractory Multiple Myeloma

Interventions

• DRUG: Daratumumab
• DRUG: Pomalidomide

Sponsor

Alliance Foundation Trials, LLC.

Collaborators

• [object Object]
• [object Object]